Journal of Ovarian Research · 2019 · 52 citations · 74 references
MedicineMolecular BiologyOncologyGene ExpressionMolecular OncologyTranscriptional RegulationCancer Cell SignalingCancer GenomicsCancer GlycobiologyCancer Stem Cell BiologyCancer Stem CellsCancer Stem Cell GlycobiologyCancer Stem-like CellsCancer-associated GlycansCopy Number SignaturesGlycosyltransferase RegulationGlycosyltransferases In CancerN-glycosylation In CancerPromoters
BACKGROUND: The ST6Gal-I glycosyltransferase, which adds α2-6-linked sialic acids to N-glycosylated proteins is upregulated in a wide range of malignancies including ovarian cancer. Prior studies have shown that ST6Gal-I-mediated sialylation of select surface receptors remodels intracellular signaling to impart cancer stem cell (CSC) characteristics. However, the mechanisms that contribute to ST6Gal-I expression in stem-like cancer cells are poorly understood. RESULTS: Herein, we identify the master stem cell transcription factor, Sox2, as a novel regulator of ST6Gal-I expression. Interestingly, SOX2 and ST6GAL1 are located within the same tumor-associated amplicon, 3q26, and these two genes exhibit coordinate gains in copy number across multiple cancers including ~ 25% of ovarian serious adenocarcinomas. In conjunction with genetic co-amplification, our studies suggest that Sox2 directly binds the ST6GAL1 promoter to drive transcription. ST6Gal-I expression is directed by at least four distinct promoters, and we identified the P3 promoter as the predominant promoter utilized by ovarian cancer cells. Chromatin Immunoprecipitation (ChIP) assays revealed that Sox2 binds regions proximal to the P3 promoter. To confirm that Sox2 regulates ST6Gal-I expression, Sox2 was either overexpressed or knocked-down in various ovarian cancer cell lines. Sox2 overexpression induced an increase in ST6Gal-I mRNA and protein, as well as surface α2-6 sialylation, whereas Sox2 knock-down suppressed levels of ST6Gal-I mRNA, protein and surface α2-6 sialylation. CONCLUSIONS: These data suggest a process whereby SOX2 and ST6GAL1 are coordinately amplified in cancer cells, with the Sox2 protein then binding the ST6GAL1 promoter to further augment ST6Gal-I expression. Our collective results provide new insight into mechanisms that upregulate ST6Gal-I expression in ovarian cancer cells, and also point to the possibility that some of the CSC characteristics commonly attributed to Sox2 may, in part, be mediated through the sialyltransferase activity of ST6Gal-I.
74
Ethan Cerami, Jianjiong Gao, Uğur Doğrusöz et al. · Cancer Discovery · 2012 · 18.4K citations · Full text
Medicine, Bioinformatics, Oncology +15
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao, Bülent Arman Aksoy, Uğur Doğrusöz et al. · Science Signaling · 2013 · 15.9K citations · Full text
Medicine, Bioinformatics, Oncology +17
Human DNA methylomes at base resolution show widespread epigenomic differences
Ryan Lister, Mattia Pelizzola, Robert H. Dowen et al. · Nature · 2009 · 4.8K citations · Full text
Multipotent cell lineages in early mouse development depend on SOX2 function
Ariel A. Avilion, Silvia K. Nicolis, Larysa Pevny et al. · Genes & Development · 2003 · 2.4K citations · Full text
Evaluating cell lines as tumour models by comparison of genomic profiles
Silvia Domcke, Rileen Sinha, Douglas A. Levine et al. · Nature Communications · 2013 · 1.5K citations · Full text